Also found in: Wikipedia.


(i-dur-sul-fase) ,


(trade name)


Therapeutic: replacement enzyme
Pharmacologic: enzymes
Pregnancy Category: C


Treatment of Mucopolysaccharidosis II (MPS II, Hunter syndrome).


Replaces an enzyme not present in Hunter syndrome. Absence of the enzyme results in cellular accumulation of aminoglycans, organomegaly and organ dysfunction.

Therapeutic effects

Improved walking capacity.


Absorption: IV administration results in complete bioavailability.
Distribution: Unknown.
Metabolism and Excretion: unknownnown.
Half-life: 44–48 min.

Time/action profile

IVrapidend of infusionunknown


Contraindicated in: No known contraindications.
Use Cautiously in: Compromised respiratory function/acute respiratory disease (increased risk of infusion reactions); Severe genetic mutations (↑ risk of serious adverse reactions)Patients at risk for fluid overload, acute respiratory disorder, cardiac or respiratory illness (↑ risk of compromised cardiac or respiratory function) Obstetric: Use in pregnancy only if clearly needed; Obstetric: Use cautiously in lactation; Pediatric: Children <16 mo (safety not established).

Adverse Reactions/Side Effects

Central nervous system

  • headache (most frequent)
  • malaise


  • hypertension


  • dyspepsia


  • cutaneous reactions (most frequent)


  • infusion site swelling


  • arthralgia (most frequent)


  • anaphylaxis (life-threatening)
  • fever (most frequent)


Drug-Drug interaction

None noted.


Intravenous (Adults and Children ≥5 yr) 0.5 mg/kg weekly


Solution for IV infusion (requires dilution): 2 mg/mL

Nursing implications

Nursing assessment

  • Observe for signs and symptoms of anaphylaxis (rash, pruritus, laryngeal edema, wheezing) during and for 24 hrs after infusion. Keep epinephrine, an antihistamine, corticosteroids, and resuscitation equipment close by in case of anaphylactic reaction.
  • Monitor for infusion-related reactions (headache, fever, rash, pruritus, erythema, urticaria, hypertension. Most reactions are managed with antihistamines and/or corticosteroids prior to or during infusions, slowing rate of infusion, and/or early discontinuation if reaction is serious.

Potential Nursing Diagnoses

Impaired physical mobility (Indications)


  • Patients with compromised respiratory function or acute respiratory disease are at increased risk of life-threatening infusion reactions. Consider delaying infusion in patients with concomitant acute respiratory and/or febrile illness.
  • Intermittent Infusion: Determine number of vials required for the dose ordered. If number of vials includes a fraction, round up to next whole number. Vials are for single use; discard remaining medication. Dilute each vial in 100 mL of 0.9% NaCl. Use an infusion set with a 0.2 micrometer filter for administration. Mix gently; do not shake solution. Solution is clear to slightly opalescent; do not administer solutions that are discolored or contain particulate matter. Solution may be stored in refrigerator for up to 48 hr. Discard solution of not administered or refrigerated within 8 hrs.
  • Rate: Administer at 8 mL/hr for first 15 min. If well tolerated, may increase by 8 mL/hr at 15 min intervals to administer total volume within desired time. Do not exceed 100 mL/hr. May slow, temporarily stop, or discontinue for that visit if infusion reactions occur. Administer total infusion over 1–3 hrs. May require longer times if infusion reactions occur; should not exceed 8 hrs.
  • Y-Site Incompatibility: Do not administer other medications or solutions in same tubing as idursulfase.

Patient/Family Teaching

  • Explain purpose of infusion to patient and parents.
  • Advise female patient to notify health care professional if pregnancy is planned or suspected or if breastfeeding.
  • Inform patient that a Hunter Outcome Survey was established to evaluate long term treatments. For information, visit or call 1–866–888–0660.

Evaluation/Desired Outcomes

  • Improved walking capacity in patients with Hunter syndrome.


a rarely used enzyme replacement.
indications This drug is used to treat mucopolysaccharidosis II.
contraindications Known hypersensitivity to this drug or other systemic antifungal or azoles, fungal meningitis, and onchomycosis or dermatomycosis in cardiac function prohibit its use.
adverse effects Adverse effects of this drug include insomnia, fever, rigors, weakness, anxiety, hypertension, hypotension, tachycardia, anemia, cramps, abdominal pain, flatulence, gynecomastia, impotence, decreased libido, malaise, hypokalemia, and tinnitus. Life-threatening side effects include GI bleeding, hepatotoxicity, toxic epidermal necrolysis, and rhabdomyolysis. Common side effects include headache, dizziness, nausea, vomiting, anorexia, diarrhea, pruritus, rash, edema, and fatigue.
Mentioned in ?
References in periodicals archive ?
This investigational formulation of idursulfase has been designed for direct administration into the cerebrospinal fluid via an intrathecal drug delivery device* (IDDD).
Shire is currently enrolling patients in its Phase 2/3 pivotal trial (HGT-HIT-094 or AIM-IT), which is a controlled, randomized, open-label, multi-center, assessor-blinded study designed to determine the effect on clinical parameters of neurodevelopmental status of monthly administration of idursulfase IT in pediatric patients with Hunter syndrome and early cognitive impairment who already receive and tolerate therapy with ELAPRASE.
For further information on the idursulfase IT pivotal trial please go to: https://clinicaltrials.
Exclusive supply drugs: Idursulfase, for health centers in the Health Logistics Platform of Seville.
Shire has manufacturing capability for agalsidase alfa, idursulfase and velaglucerase alfa at its protein manufacturing plant in Cambridge, Massachusetts, US for its HGT products, REPLAGAL, ELAPRASE and VPRIV.
The Shire platform for direct delivery of proteins to the CNS was advanced in the first quarter of 2010 with the initiation of intrathecal delivery of idursulfase in the Phase 1/2 study in Hunter syndrome.